

In the Claims:

Claim 1 (currently amended): A modified antiangiogenic peptide comprising a peptide corresponding to a region of mammalian plasminogen, and a reactive group which reacts with amino groups, hydroxyl groups, or thiol groups on blood components to form stable covalent bonds wherein said reactive group is selected from the group consisting of succinimidyl and maleimido groups.

Claim 2 (previously amended): The modified peptide of claim 1 wherein said peptide is a kringle 5 peptide.

Claim 3 (previously amended): The modified peptide of claim 2 wherein said modified peptide is reactive with blood proteins.

Claim 4 (previously amended): The modified peptide of claim 3, wherein the modified peptide is reactive with a thiol group on a blood protein.

Claim 5 (previously amended): The modified peptide of claim 2 wherein the peptide is selected from the group consisting of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, and SEQ ID NO:9.

Claim 6 (previously amended): The modified peptide of claim 2 wherein the peptide is selected from the group consisting of SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15 and SEQ ID NO:16.

Claims 7-9 (cancelled)

Claim 10 (currently amended): A ~~derivative of a~~ modified kringle 5 peptide, said ~~derivative~~ comprising a kringle 5 peptide and a maleimido group which reacts with a thiol group on human serum albumin to form a covalent bond.

Claim 11 (currently amended): The ~~derivative~~ modified kringle 5 peptide of claim 10, wherein said kringle 5 peptide is selected from SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8 and SEQ ID NO:9.

Claim 12 (currently amended): The ~~derivative~~ modified kringle 5 peptide of claim 10, wherein said kringle 5 peptide is selected from SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15 and SEQ ID NO:16.

Claims 13-18 (cancelled)

Claim 19 (original): A modified kringle 5 peptide selected from the group consisting of NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Lys-NH₂; NAc-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-NH₂; Nac-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-NH₂; NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Ala-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-NH₂; NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Lys-NH₂; NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-(Nε-MPA)-NH₂; (MPA-AEEA)-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH₂ and (MPA)-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH₂.

Claim 20 (original): A modified kringle 5 peptide selected from the group consisting of: NAc-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-(Nε-MPA)-NH₂; (MPA-AEEA)-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH₂; (MPA)-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH₂; NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Ala-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-(Nε-MPA)-NH₂;

(MPA-AEEA)-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Ala-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH₂; and

(MPA)-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Ala-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH₂.

Claim 21 (currently amended): A ~~derivative of~~ modified kringle 5 peptide selected from the group consisting of NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Lys-(Nε-MPA)-NH₂; MPA-AEEA)-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-NH₂; (MPA)-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-NH₂; NAc-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-(Nε-MPA)-NH₂; (MPA-AEEA)-Arg-Lys-Leu-Tyr-Asp-Tyr-NH₂; (MPA)-Arg-Lys-Leu-Tyr-Asp-Tyr-NH₂; NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Lys-(Nε-MPA)-NH₂; (MPA-AEEA)-Pro-Arg-Lys-Leu-Tyr-Asp-NH₂; (MPA)-Pro-Arg-Lys-Leu-Tyr-Asp-NH₂; NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-(Nε-AEEA-MPA)-NH₂; and NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-(Nε-AEEA_n-MPA)-NH₂.